Eli Lilly (NYSE: LLY) to Announce Q4 2025 Financial Results on February 4, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Should l Buy LLY?
Source: Newsfilter
- Earnings Announcement: Eli Lilly is set to release its fourth-quarter 2025 financial results on February 4, 2026, which is expected to provide investors with critical financial data to assess the company's performance.
- Conference Call Details: On the same day, Lilly will conduct a conference call at 10 a.m. Eastern Time to elaborate on its financial performance, enhancing communication with investors and the media.
- Live Webcast Access: Investors and the general public can access the live webcast of the conference call through a link on Lilly's website, ensuring transparency and broadening audience reach to enhance the company's image.
- Commitment to Diversity: Lilly is dedicated to reflecting global diversity through innovative clinical trials, advancing drug development to tackle significant health challenges worldwide, thereby reinforcing its leadership position in the pharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 983.260
Low
950.00
Averages
1192
High
1500
Current: 983.260
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Launches Zepbound® KwikPen® to Enhance Obesity Treatment Access
- Platform Launch: Eli Lilly has introduced the Employer Connect platform, aimed at collaborating with independent program administrators to provide flexible obesity management medication solutions, thereby improving access for over 100 million American adults and potentially enhancing healthcare coverage for obesity patients significantly.
- Cost Reduction: The Zepbound® KwikPen® is priced at $449, and with flexible cost-sharing options, employers can offer more affordable obesity treatment to employees, which is expected to improve treatment adherence and overall health outcomes among the workforce.
- Clinical Trial Results: In the SURMOUNT-1 trial, adults taking Zepbound 15mg lost an average of 20.9% of their body weight over 72 weeks, compared to just 3.1% in the placebo group, demonstrating the drug's significant efficacy in obesity management, which could drive its widespread adoption in the market.
- Strong Market Demand: Zepbound was the most prescribed weight management medication in the U.S. in 2025, and with FDA approval, it is expected to further increase its market share in obesity treatment, addressing the growing patient demand effectively.
See More
Healthcare Sector Employment Data Raises Concerns
- Deteriorating Employment Data: The U.S. lost 92,000 jobs in February, with the unemployment rate rising to 4.4%, significantly exceeding the expected 55,000 job losses, indicating signs of economic slowdown that could impact the stability of the healthcare sector.
- Healthcare Job Losses: The healthcare sector unexpectedly lost 28,000 jobs in February, partly due to strikes by Kaiser Permanente employees, a shift that may undermine investor confidence in the healthcare sector and affect related ETFs' performance.
- Social Assistance Bright Spot: Despite the overall labor market weakness, the social assistance sector added approximately 9,000 jobs in February, demonstrating resilience that could provide support for the healthcare industry.
- Market Signal: The slowdown in employment growth within the healthcare sector may have spillover effects on broader market ETFs, reminding investors that even the most stable sectors are not entirely insulated from economic cycles.
See More
Supreme Court Overturns Trump's Tariffs, Economic Implications Ahead
- Tariff Policy Change: The U.S. Supreme Court has overturned Trump's tariffs, affecting approximately $170 billion in tariffs; while some tariffs are lifted, the compensation issue remains unresolved, impacting cost structures and future profitability for affected companies.
- Economic Growth Slowdown: The latest GDP growth rate stands at 1.4%, below expectations, with consumer spending growth decelerating from 3.5% to 2.4%, indicating fragility in economic recovery that may lead to cautious corporate investment and expansion decisions.
- Inflationary Pressures: The core inflation rate has risen by 3% year-over-year, exceeding market expectations; although the market's initial reaction was muted, persistent high inflation could undermine consumer confidence and spending, posing risks to economic growth.
- Retail Market Dynamics: Walmart's earnings report indicates that high-income consumers continue to spend, while lower-income groups are cutting back due to rising costs, reflecting economic imbalances that may prompt retailers to adjust pricing strategies and market approaches.
See More
US-Israel Conflict Escalates, Pharma Stocks as Safe Haven
- Market Turmoil Intensifies: The escalation of the US-Israel conflict against Iran has roiled global markets, with oil prices surging above $100 per barrel this week while US stocks plummeted due to limited trade and travel.
- Weakening Safe Havens: Traditional safe-haven assets like spot gold have fallen over 2% in the past five days, on track for their first weekly decline in over a month, while consumer staples are pressured by rising oil prices, impacting low-end consumers and increasing input costs for companies.
- Defensive Pharma Stocks: UBS analysts highlight the pharmaceutical sector as the most defensive, with over three dozen stocks, including Eli Lilly and Merck, expected to thrive amid Middle East tensions, as Eli Lilly has risen 34% in the past six months.
- Opportunities in AI Era: Pharmaceutical stocks are also seen as winners in the generative AI era, as AI tools are likely to enhance R&D productivity, and the sector's relatively cheap valuations and low leverage position it well during rising credit spreads.
See More
Lilly Pledges $1.68 Million to WHO Foundation by 2029 to Enhance Health Systems for Obesity Treatment
Funding Announcement: The WHO Foundation has committed $1.68 million to support efforts aimed at strengthening health systems for obesity care.
Long-term Support: This funding is designated to continue until 2029, indicating a sustained investment in health initiatives related to obesity.
See More
WHO Foundation Partners with Lilly to Enhance Health Systems for Obesity Treatment
Collaboration Announcement: The WHO Foundation has announced a partnership with Lilly to enhance health systems focused on obesity care.
Objective of Partnership: The collaboration aims to strengthen healthcare responses and improve treatment options for individuals affected by obesity.
See More
Eli Lilly Launches Zepbound® KwikPen® to Enhance Obesity Treatment Access
- Platform Launch: Eli Lilly has introduced the Employer Connect platform, aimed at collaborating with independent program administrators to provide flexible obesity management medication solutions, thereby improving access for over 100 million American adults and potentially enhancing healthcare coverage for obesity patients significantly.
- Cost Reduction: The Zepbound® KwikPen® is priced at $449, and with flexible cost-sharing options, employers can offer more affordable obesity treatment to employees, which is expected to improve treatment adherence and overall health outcomes among the workforce.
- Clinical Trial Results: In the SURMOUNT-1 trial, adults taking Zepbound 15mg lost an average of 20.9% of their body weight over 72 weeks, compared to just 3.1% in the placebo group, demonstrating the drug's significant efficacy in obesity management, which could drive its widespread adoption in the market.
- Strong Market Demand: Zepbound was the most prescribed weight management medication in the U.S. in 2025, and with FDA approval, it is expected to further increase its market share in obesity treatment, addressing the growing patient demand effectively.
See More
Healthcare Sector Employment Data Raises Concerns
- Deteriorating Employment Data: The U.S. lost 92,000 jobs in February, with the unemployment rate rising to 4.4%, significantly exceeding the expected 55,000 job losses, indicating signs of economic slowdown that could impact the stability of the healthcare sector.
- Healthcare Job Losses: The healthcare sector unexpectedly lost 28,000 jobs in February, partly due to strikes by Kaiser Permanente employees, a shift that may undermine investor confidence in the healthcare sector and affect related ETFs' performance.
- Social Assistance Bright Spot: Despite the overall labor market weakness, the social assistance sector added approximately 9,000 jobs in February, demonstrating resilience that could provide support for the healthcare industry.
- Market Signal: The slowdown in employment growth within the healthcare sector may have spillover effects on broader market ETFs, reminding investors that even the most stable sectors are not entirely insulated from economic cycles.
See More
Supreme Court Overturns Trump's Tariffs, Economic Implications Ahead
- Tariff Policy Change: The U.S. Supreme Court has overturned Trump's tariffs, affecting approximately $170 billion in tariffs; while some tariffs are lifted, the compensation issue remains unresolved, impacting cost structures and future profitability for affected companies.
- Economic Growth Slowdown: The latest GDP growth rate stands at 1.4%, below expectations, with consumer spending growth decelerating from 3.5% to 2.4%, indicating fragility in economic recovery that may lead to cautious corporate investment and expansion decisions.
- Inflationary Pressures: The core inflation rate has risen by 3% year-over-year, exceeding market expectations; although the market's initial reaction was muted, persistent high inflation could undermine consumer confidence and spending, posing risks to economic growth.
- Retail Market Dynamics: Walmart's earnings report indicates that high-income consumers continue to spend, while lower-income groups are cutting back due to rising costs, reflecting economic imbalances that may prompt retailers to adjust pricing strategies and market approaches.
See More
US-Israel Conflict Escalates, Pharma Stocks as Safe Haven
- Market Turmoil Intensifies: The escalation of the US-Israel conflict against Iran has roiled global markets, with oil prices surging above $100 per barrel this week while US stocks plummeted due to limited trade and travel.
- Weakening Safe Havens: Traditional safe-haven assets like spot gold have fallen over 2% in the past five days, on track for their first weekly decline in over a month, while consumer staples are pressured by rising oil prices, impacting low-end consumers and increasing input costs for companies.
- Defensive Pharma Stocks: UBS analysts highlight the pharmaceutical sector as the most defensive, with over three dozen stocks, including Eli Lilly and Merck, expected to thrive amid Middle East tensions, as Eli Lilly has risen 34% in the past six months.
- Opportunities in AI Era: Pharmaceutical stocks are also seen as winners in the generative AI era, as AI tools are likely to enhance R&D productivity, and the sector's relatively cheap valuations and low leverage position it well during rising credit spreads.
See More
Lilly Pledges $1.68 Million to WHO Foundation by 2029 to Enhance Health Systems for Obesity Treatment
Funding Announcement: The WHO Foundation has committed $1.68 million to support efforts aimed at strengthening health systems for obesity care.
Long-term Support: This funding is designated to continue until 2029, indicating a sustained investment in health initiatives related to obesity.
See More
WHO Foundation Partners with Lilly to Enhance Health Systems for Obesity Treatment
Collaboration Announcement: The WHO Foundation has announced a partnership with Lilly to enhance health systems focused on obesity care.
Objective of Partnership: The collaboration aims to strengthen healthcare responses and improve treatment options for individuals affected by obesity.
See More
